Information on the compensation of corporate officers

(in application of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code)

The combined general meeting of MaaT Pharma (the “**Company**”) which was held on June 16, 2026 9.30 a.m. CET at the registered office of the Company located 70 avenue Tony Garnier – 69007 Lyon, approved the resolution relating to the compensation policy for corporate officers in respect of the 2026 financial year (*Say on Pay ex-ante*), as well as the resolution relating to the information mentioned in I. of article L. 22-10-9 of the French Commercial Code (*Code de commerce*) relating to the compensation paid and/or granted to corporate officers in respect of the financial year ending December 31, 2025 (so-called "global" *Say on Pay ex-post*).

Pursuant to the provisions of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code, this information is presented below, supplemented for information purposes by the results of the votes on the resolutions relating to the individual compensation paid and/or allocated to the Company's corporate officers in respect of the financial year ending December 31, 2025 (so-called "individual" *Say on Pay ex-post*).

Resolution	Description	Results of the votes	Corresponding section in the 2025 Universal Registration Document (URD)
TWELFTH RESOLUTION	Approval of the information relating to the remuneration of corporate officers for the year 2025 mentioned in I of Article L. 22-10-9 of the French Commercial Code	**Approved by 96,57%**	**Universal Registration Document (Section 13 of the URD); Paragraph 13.2** (*Ratio*)
THIRTEENTH RESOLUTION	Approval of the elements of compensation paid during or allocated by way of the financial year 2025 to the Chairman of the Board of Directors	**Approved by 99,89%**	**Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1** *(Corporate officers Compensation - Chairman of the Board of Directors)*

FOURTEENTH RESOLUTION	Approval of the elements of compensation paid during or allocated by way of the financial year 2025 to the Chief Executive Officer	**Approved by 96,52%**	**Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2** *(Corporate officers Compensation - CEO)*
FIFTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2026 to the Chairman of the Board of Directors	**Approved by 99,46%**	**Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1** (*Corporate officers Compensation - Chairman of the Board of Directors*)
SIXTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2026 to the Chief Executive Officer	**Approved by 96,50%**	**Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2** (*Corporate officers Compensation - CEO*)
SEVENTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2026 to directors	**Approved by 95,50%**	**Universal Registration Document (Section 13 of the URD); Paragraph 13.1.2** (*Director's compensation)*

About MaaT Pharma

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.

As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.

Contacts

MaaT Pharma – Investor Relations
Eric Soyer
Chief Financial Officer
+33 4 28 29 14 00
invest@maat-pharma.com

MaaT Pharma – Media Relations
Pauline Richaud
Head of Communications
+33 6 14 06 45 92
media@maat-pharma.com